Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). CureVac NV's share price for the quarter that ended in Dec. 2023 was $4.21. CureVac NV's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 223.99 Mil. Therefore, CureVac NV's market cap for the quarter that ended in Dec. 2023 was $942.99 Mil.
CureVac NV's quarterly market cap
declined
from Jun. 2023 ($2,332.86 Mil) to Sep. 2023 ($1,529.40 Mil) and
declined
from Sep. 2023 ($1,529.40 Mil) to Dec. 2023 ($942.99 Mil).
CureVac NV's annual market cap
declined
from Dec. 2021 ($6,420.12 Mil) to Dec. 2022 ($1,175.57 Mil) and
declined
from Dec. 2022 ($1,175.57 Mil) to Dec. 2023 ($942.99 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CureVac NV's Enterprise Value for Today is $312.28 Mil.
CureVac NV Market Cap Historical Data
The historical data trend for CureVac NV's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CureVac NV's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CureVac NV's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CureVac NV's Market Cap distribution charts can be found below:
* The bar in red indicates where CureVac NV's Market Cap falls into.
CureVac NV Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
CureVac NV's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CureVac NV (NAS:CVAC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
CureVac NV Market Cap Related Terms
Thank you for viewing the detailed overview of CureVac NV's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CVAC has been successfully added to your 